S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
Bank Accounts: Frozen! (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
Unusual Passive Income Investment (Found on a Golf Course) (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
Here’s Your Own Billion-Dollar Trading Edge (Just $0.76 a Week) (Ad)pixel
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
Bank Accounts: Frozen! (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
Unusual Passive Income Investment (Found on a Golf Course) (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
Here’s Your Own Billion-Dollar Trading Edge (Just $0.76 a Week) (Ad)pixel
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
Bank Accounts: Frozen! (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
Unusual Passive Income Investment (Found on a Golf Course) (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
Here’s Your Own Billion-Dollar Trading Edge (Just $0.76 a Week) (Ad)pixel
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
Bank Accounts: Frozen! (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
Unusual Passive Income Investment (Found on a Golf Course) (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
Here’s Your Own Billion-Dollar Trading Edge (Just $0.76 a Week) (Ad)pixel
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
NYSEARCA:PRME

Prime Medicine - PRME Price, Holdings, & News

$12.28
-0.25 (-2.00%)
(As of 03/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$12.16
▼
$12.67
50-Day Range
$11.21
▼
$21.11
52-Week Range
$11.07
▼
$21.73
Volume
134,379 shs
Average Volume
166,618 shs
Market Capitalization
$1.16 billion
Assets Under Management
$1.03 million
Dividend Yield
N/A
Net Expense Ratio
0.95%
PRME stock logo

About Prime Medicine (NYSEARCA:PRME)

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Receive PRME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter.

PRME ETF News Headlines

March 27, 2023 | finance.yahoo.com
Prime Medicine to Present at Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days
March 9, 2023 | finance.yahoo.com
Prime Medicine Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 31, 2023 | Weiss Ratings (Ad)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
January 9, 2023 | finance.yahoo.com
Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities
January 3, 2023 | finance.yahoo.com
Prime Medicine to Present at 41st Annual J.P. Morgan Healthcare Conference
December 15, 2022 | apnews.com
Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
November 19, 2022 | cnbc.com
'Compelling' and 'attractive': These stocks are firing on all cylinders, JPMorgan says
November 15, 2022 | cnbc.com
This gene-editing company that went public last month could rally 20%, Jefferies says
March 31, 2023 | Investor Place Media (Ad)
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
November 10, 2022 | reuters.com
Prime Medicine Inc
See More Headlines
Receive PRME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer
First Trust
Fund Name
First Trust Heitman Global Prime Real Estate ETF
Tax Classification
Regulated Investment Company
Stock Exchange
NYSEARCA
Current Symbol
NYSEARCA:PRME
Inception Date
11/12/2015
Fund Manager
Jerry Ehlinger, John White, Jacques Perdrix, Andreas Welter
Web
www.primemedicine.com
Phone
N/A

Fund Focus

Asset Class
Real Estate
Benchmark
N/A
Category
Real Estate
Focus
Real Estate
Development Level
Blended Development
Region
Global
Number of Holdings
0

Fund Statistics

Assets Under Management
$1.03 million
Average Daily Volume
$213.00
Discount/Premium
3.91%

Administrator, Advisor and Custodian

Administrator
Brown Brothers Harriman & Co.
Advisor
First Trust Advisors L.P.
Custodian
Brown Brothers Harriman & Co.
Distributor
First Trust Portfolios L.P.
Transfer Agent
Brown Brothers Harriman & Co.
Trustee
N/A
Lead Market Maker
Credit Suisse

Miscellaneous

Outstanding Shares
94,336,000
Beta
N/A

Prime Medicine Expenses

TypePRMEReal Estate ETFsReal Estate ETFsNYSEARCA ETFsAll ETFs
Management Fee0.95%0.45%0.44%0.49%0.49%
Other Expenses0.00%0.19%0.22%0.58%0.55%
Total Expense0.95%0.50%0.50%0.70%0.68%
Fee Waiver0.00%-0.20%-0.19%-0.63%-0.57%
Net Expense0.95%0.47%0.47%0.56%0.56%

Prime Medicine (PRME)

Full Holdings Details

Key Executives

  • Dr. Keith Michael Gottesdiener M.D. (Age 69)
    Pres, CEO, Sec. & Director
    Comp: $867.11k
  • Dr. Ann L. Lee Ph.D. (Age 61)
    Chief Technical Officer
    Comp: $171.19k
  • Dr. Jeremy S. Duffield M.D. (Age 55)
    Ph.D., Chief Scientific Officer
    Comp: $994.4k
  • Dr. Andrew Anzalone M.D. (Age 37)
    Ph.D., Co-Founder, Sr. Scientist II, Head of Prime Editing Platform & Head of Platform Devel.
  • Dr. David R. Liu Ph.D.
    Co-Founder & Chair of Scientific Advisory Board
  • Ms. Carman Alenson CPA (Age 58)
    M.B.A., Chief Accounting Officer & Interim CFO
  • Dr. Meredith Goldwasser (Age 52)
    Sr. VP of Strategy & Corp. Operations and Head of Strategy & Corp. Operations
  • Dr. Karen Brown J.D.
    Ph.D., Sr. VP of Intellectual Property & Legal Affairs
  • Ms. Niamh Alix
    Chief HR Officer
  • Mr. Richard Brudnick (Age 65)
    Chief Bus. Officer

Similar ETFs

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PRME ETF - Frequently Asked Questions

Should I buy or sell Prime Medicine stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prime Medicine in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRME shares.
View PRME analyst ratings or view top-rated stocks.

What is Prime Medicine's stock price forecast for 2023?

4 equities research analysts have issued 1 year price objectives for Prime Medicine's stock. Their PRME share price forecasts range from $21.00 to $27.00. On average, they expect the company's share price to reach $23.75 in the next year. This suggests a possible upside of 93.4% from the stock's current price.
View analysts price targets for PRME or view top-rated stocks among Wall Street analysts.

How have PRME shares performed in 2023?

Prime Medicine's stock was trading at $18.58 at the beginning of the year. Since then, PRME stock has decreased by 33.9% and is now trading at $12.28.
View the best growth stocks for 2023 here.

What does PRME invest in?

Prime Medicine is a real estate fund issued by First Trust. PRME focuses on real estate investments. The fund's investments total to approximately $1.03 million assets under management.

What is the management fee for Prime Medicine?

Prime Medicine's management fee is 0.95% and has no other recorded expenses or fee waivers. The net expense ratio for PRME is 0.95%.

What is Prime Medicine's stock symbol?

Prime Medicine trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "PRME."

When does the company's lock-up period expire?

Prime Medicine's lock-up period expires on Tuesday, April 18th. Prime Medicine had issued 10,294,118 shares in its IPO on October 20th. The total size of the offering was $175,000,006 based on an initial share price of $17.00. After the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Who are Prime Medicine's major shareholders?

Prime Medicine's stock is owned by a variety of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (2.52%), ARK Investment Management LLC (1.74%), EcoR1 Capital LLC (0.64%), Moore Capital Management LP (0.53%), Sumitomo Mitsui Trust Holdings Inc. (0.52%) and Nikko Asset Management Americas Inc. (0.52%). Insiders that own company stock include 2019 Gp LLC Gv and Thomas Cahill.
View institutional ownership trends.

How do I buy shares of Prime Medicine?

Shares of PRME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prime Medicine's stock price today?

One share of PRME stock can currently be purchased for approximately $12.28.

How much money does Prime Medicine make?

Prime Medicine (NYSEARCA:PRME) has a market capitalization of $1.16 billion.

This page (NYSEARCA:PRME) was last updated on 3/31/2023 by MarketBeat.com Staff